1.Product Overview

Product Name	Valganciclovir Tablets, USP
Reference Listed Drug (RLD)	Xarelto®(Janssen)
Pharmaceutical Form	Film-coated tablet
Strength	450 mg

2.Indications and Usage

Valganciclovir is a prodrug of ganciclovir that is indicated for:

Adult Patients	Treatment of CMV Retinitis	In patients with Acquired Immunodeficiency Syndrome (AIDS)
	Prevention of CMV Disease	In kidney, heart, or kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-])
Pediatric Patients	Prevention of CMV Disease: In kidney transplant patients (4 months to 16 years) and heart transplant patients (1 month to 16 years) at high risk

3.Dosage and Administration

Important Administration Instructions Caution	Valganciclovir tablets should be taken with food.
	Valganciclovir tablets are a prodrug of ganciclovir; oral valganciclovir 900 mg provides systemic ganciclovir exposure comparable to IV ganciclovir 5 mg/kg.
	Dosage must be adjusted according to patient's renal function (Creatinine Clearance, CrCl).

Standard Adult Dosing:

Indication	Dosage	Duration
CMV Retinitis (Treatment)	Induction: 900 mg (two 450 mg tablets) twice daily	21 days
	Maintenance: 900 mg (two 450 mg tablets) once daily	-
CMV Disease (Prevention)	900 mg (two 450 mg tablets) once daily	Start within 10 days of transplant, continue until 100 days post-transplant.

4.Comparison of Oral Antivirals for CMV Management

Feature	Valganciclovir (Generic)	Ganciclovir (Oral)	Letermovir
Mechanism of Action (MOA)	Prodrug of Ganciclovir. Inhibits viral DNA synthesis by competing with deoxyguanosine triphosphate.	Ganciclovir. Inhibits viral DNA synthesis. (Same active moiety as Valganciclovir.)	CMV Terminase Complex Inhibitor. Inhibits viral DNA processing and packaging.
Primary Oral Indication(s)	Treatment of CMV retinitis. Prevention of CMV disease in solid organ transplant (SOT).	Prevention of CMV disease in transplant recipients. Maintenance for CMV retinitis (less common).	Prevention of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
Bioavailability (Oral)	High (~60%)	Very Low (~6–9%)	Moderate (Varies with/without cyclosporine).
Standard Adult Dosing	900 mg once or twice daily (depending on indication).	1000 mg three times daily.	480 mg once daily.
Key Differentiator	High bioavailability allows for once/twice-daily dosing, replacing IV ganciclovir.	Low bioavailability requires frequent dosing (TID) and large pill burden.	Novel MOA; specifically for CMV prophylaxis in the HSCT setting.

5.Advantages of Our Generic Valganciclovir Tablets

Cost-Effectiveness	Provides a highly effective antiviral therapy at a more accessible price point compared to the brand-name drug, reducing the financial burden on patients and payers.
Therapeutic Equivalence (A-Rated)	As an FDA-approved generic (ANDA 218027), it is bioequivalent to the reference drug (Valcyte®), ensuring the same safety, efficacy, and clinical outcomes.
cGMP Manufacturing Standards	Manufactured in strict accordance with FDA regulations and Current Good Manufacturing Practices (cGMP), guaranteeing consistent product quality and purity.